Neurocrine Biosciences Insider Unloads $7.8mln in Shares According to Recent SEC Filing

Neurocrine Biosciences insider sold shares worth $7.8 million, according to an SEC filing. The company is a neuroscience-focused biopharmaceutical firm with FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids, as well as a robust pipeline in mid-to late-phase clinical development. Commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn.

Neurocrine Biosciences Inc (NASDAQ:NBIX), a leading neuroscience-focused biopharmaceutical company, has seen significant insider trading activity. On July 9, 2025, Chief Scientific Officer Onyia Jude sold 59,819 shares of common stock, totaling approximately $7.8 million [2]. The transaction was executed at a weighted average price of $130.455 per share, with individual transactions ranging from $130.00 to $131.45.

Jude also exercised options to acquire 59,819 shares at a price of $84.74 per share, valued at $5,069,062. Following these transactions, Jude directly owns 18,289 shares of Neurocrine Biosciences [2].

Neurocrine Biosciences has been making strides in the biopharmaceutical sector. The company has FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids. Additionally, Neurocrine has a robust pipeline in mid-to-late phase clinical development, with commercial products including INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn [1].

Recent developments have bolstered investor confidence. Goldman Sachs initiated coverage on Neurocrine with a Buy rating, projecting a compound annual growth rate of 11% through 2030. UBS raised its price target for Neurocrine to $174, citing positive indicators for the Crenessity drug launch and expectations of continued robust patient additions [1]. Neurocrine also presented new data showing that its drug Ingrezza significantly reduces cognitive and motor burdens in Huntington’s disease and enhances quality of life for older adults with tardive dyskinesia [1].

In a strategic move, Neurocrine appointed Lewis Choi as Chief Information Officer, bringing extensive experience in IT and AI to bolster the company’s technology strategy [1].

References:
[1] https://www.tradingview.com/news/tradingview:07f67b7aaf5a0:0-neurocrine-biosciences-chief-scientific-officer-sells-shares/
[2] https://www.investing.com/news/insider-trading-news/neurocrine-biosciences-nbix-cso-onyia-sells-78m-in-stock-93CH-4132621